In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Probiodrug AG

www.probiodrug.de

Latest From Probiodrug AG

Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach

Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.

ImmunoOncology Deals

Probiodrug CEO Outlines Phase IIb Plans For Potential Alzheimer’s Treatments

Probiodrug is ramping up plans to run Phase IIb Alzheimer's disease trials on the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy. CEO Konrad Glund spoke to Scrip at the 2018 Biotech Showcase.

Business Strategies Companies

Boost For European Biotech As €345m Fund Opens

Edmond De Rothschild Investment Partners unveils the largest life science and medical device venture fund to be raised in Europe. Olivier Litzka tells Scrip that the continent can now boast a public market machinery that contributes to potentially lucrative exits for investors.

Financing StartUps and SMEs

CNS IPOs Follow Broad Industry Trends

Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Probiodrug AG
  • Senior Management
  • Konrad Glund, PhD, CEO
    Hendrick Liebers, CFO
    Ronald Black, MD, CMO
    Inge Lues, PhD, Chief Dev. Officer
  • Contact Info
  • Probiodrug AG
    Phone: (49) 345 555 9900
    Weinbergweg 22
    Halle/Saale, D-06120
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register